Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial

• Published in: The lancet oncology Vol. 25; no. 1; pp. 76 - 85
• Main Authors: Li, Kezhen, Chen, Jing, Hu, Yingjie, Wang, Yan-Zhou, Shen, Yuanming, Chen, Gang, Peng, Wenju, Fang, Zixuan, Xia, Bairong, Chen, Xiaojun, Song, Kun, Wang, Yingmei, Zou, Dongling, Wang, Yan-Chun, Han, Yingyan, Feng, Xue, Yuan, Jing, Guo, Shuaiqingying, Meng, Xiaolin, Feng, Chenzhao, Chen, Yin, Yang, Jie, Fan, Junpeng, Wang, Jianliu, Ai, Jihui, Ma, Ding, Sun, Chaoyang
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.01.2024; Elsevier Limited
• Subjects: Adverse events; Biomarkers; Cancer therapies; Cervical cancer; Chemoradiotherapy; Chemotherapy; Cisplatin; Contraindications; Gynecology; Hematology, Oncology, and Palliative Medicine; Hysterectomy; Immune checkpoint inhibitors; Immunotherapy; Laboratories; Leukopenia; Lymphatic system; Lymphopenia; Neutropenia; Obstetrics; Paclitaxel; Patients; Radiation therapy; Response rates; Risk factors; Solid tumors; Surgery; Toxicity; Tumors; United States > US; China

Locally advanced cervical cancer constitutes around 37% of cervical cancer cases globally and has a poor prognosis due to limited therapeutic options. Immune checkpoint inhibitors in the neoadjuvant setting could address these challenges. We aimed to investigate the efficacy and safety of neoadjuvan...